Induction therapy in renal transplantation

Current Opinion in Organ Transplantation

Volumn 6, Issue 4, 2001, Pages 320-326

  Shidban, Hamid ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD40 LIGAND; CYCLOSPORIN; CYTOTOXIC ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ODULIMOMAB; OKT 3; POLYCLONAL ANTIBODY; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANTIBODY DETECTION; ASEPTIC MENINGITIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DYSPNEA; GASTROINTESTINAL SYMPTOM; GRAFT PATENCY; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; RABBIT; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 0035680515     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075200-200112000-00009     Document Type: Review

References (39)

1. Effect of antithymocyte globulin induction treatment on renal transplant outcome
2. Low dose antithymocyte globulins in renal transplantation
3. A randomized, double blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients
4. Results of the double blind randomized multicenter phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation
5. Immediate and long term results of ATG induction therapy for delayed graft function compared with conventional therapy for immediate graft function
6. Preoperative single high dose ATG-Fersenius S administration as induction immunosuppressive therapy in cadaveric renal transplantation - Preliminary results
7. Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells
8. Effect of antilymphocyte induction therapy on renal allograft survival: A meta analysis
9. The use of thymoglobulin induction in renal transplantation: A pharmacovigilance study
10. Induction therapy with rabbit antilymphocyte sera reduces rejection episodes in immunologically low risk living donor renal transplant recipients
11. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporine after renal transplantation
12. Reduced human IgG anti-Atgam antibody formation in renal transplant recipients receiving mycophenolate mofetil
13. Advantage of antithymocyte globulin induction in sensitized kidney recipients: A randomized prospective study comparing induction with and without antithymocyte globulin
14. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation
15. Low-dose OKT3 induction therapy following renal transplantation: A controlled study
16. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants
17. A prospective, double blind, randomized study of high-versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation
18. OKT3 induction therapy: Influence of duration on rejections and infections
19. OKT3 induction therapy and cadaveric renal transplantation in black patients
20. The impact of quadruple immunosuppression with OKT3 on kidney transplantation in lack recipients
21. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: A prospective randomized study
22. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: Patient and graft survival, CD3 subset, infection, and cost analysis
23. A review of interleukin-2 receptor antagonists in solid organ transplantation
24. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation
25. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation
26. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
27. Reduction of acute renal allograft rejection by Daclizumab. Daclizumab Double Therapy Study Group
28. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group
29. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis
30. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation
31. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression
32. The effect of Daclizumab in a high-risk renal transplant population
33. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group
34. Reduction of the occurrence of acute cellular re-ejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group
35. Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors
36. Adhesion molecule expression (ICAM-1, VCAM-1, E-selectin and PECAM) in human kidney allografts
37. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: A report of the European Anti-ICAM-1 Renal Transplant Study Group
38. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantation
39. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates